Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Third Quarter 2024 Earnings Conference Call. [Operator Instructions] ...

LOTIS-5 full enrollment and LOTIS-7 initial efficacy, safety update anticipated by end of 2024 Updated ZYNLONTA® Phase 2 ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with me ...

Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting ...

Good day and welcome to the FibroGen third-quarter 2024 earnings conference call. (Operator Instructions) Please note this event is being recorded. I would now like to hand the call over to David ...

Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

Renesas has expanded its Arm Cortex-M85-based RA8 series to include two new entry-level MCUs, RA8E1 and RA8E2. The new ...

Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.

The full interim unaudited condensed consolidated financial statements can be found in BioNTech’s Report on Form 6-K for the period ended September ... (“TROP2”)-targeted antibody-drug conjugate (“ADC ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, thank you for joining us today. Welcome to ...